Cargando…
Pin1 inhibition improves the efficacy of ralaniten compounds that bind to the N-terminal domain of androgen receptor
Therapies for lethal castration-resistant prostate cancer (CRPC) are an unmet medical need. One mechanism underlying CRPC and resistance to hormonal therapies is the expression of constitutively active splice variant(s) of androgen receptor (AR-Vs) that lack its C-terminus ligand-binding domain. Tra...
Autores principales: | Leung, Jacky K., Imamura, Yusuke, Kato, Minoru, Wang, Jun, Mawji, Nasrin R., Sadar, Marianne D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985297/ https://www.ncbi.nlm.nih.gov/pubmed/33753863 http://dx.doi.org/10.1038/s42003-021-01927-3 |
Ejemplares similares
-
Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1
por: Obst, Jon K., et al.
Publicado: (2022) -
Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
por: Banuelos, Carmen A., et al.
Publicado: (2020) -
SAT022 A Mechanism Of Resistance To Novel Inhibitors Of The N-Terminal Domain Of Androgen Receptor
por: Setiawan, Josie, et al.
Publicado: (2023) -
Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers
por: Tien, Amy H., et al.
Publicado: (2022) -
Characterization of Niphatenones that Inhibit Androgen Receptor N-Terminal Domain
por: Banuelos, Carmen A., et al.
Publicado: (2014)